er-086526 and Leukopenia

Eribulin is a novel antimicrotubule drug, which is approved in the second line treatment of advanced breast cancer in patients who received anthracyclines and taxanes. The article presents the results of two huge phase III clinical trials (301, 305) and their pooled analysis. Eribulin monotherapy demonstates staistically significant improved overall survival compared to standart treatments (15.2 mnths vs 12.8 mnths, p = 0.03 in pooled analysis). Certain subgroups of patients--Her2-negative and triple-negative have the most survival benefit. According to own experience with Eribulin inside the clinical trials, presented in the article, the drug is effective and well tolerated even by older patients.

Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female; Furans; Humans; Kaplan-Meier Estimate; Ketones; Leukopenia; Meta-Analysis as Topic; Microtubules; Neutropenia; Severity of Illness Index; Treatment Outcome; Triple Negative Breast Neoplasms